Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's...
13 insider purchases on record · latest filing 2025-12-12.
Insiders have also filed 251 sale transactions at IMVT.